Skip to content

Released May 9, 2023, before the open

10-Q filed May 9, 2023, 39 days after period end · 0001576885-23-000025

Q1 2023 · 10-Q
Revenue—
Net Income-$11.31MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.28N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$13,135,000N/M
Operating Cash Flow-$10,175,000N/M
Free Cash Flowderived-$10,175,000N/M

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021
Net Income-$11.31M-$9.13M-$27.00M
EPS Diluted-$0.28-$0.23-$64.41

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR